About this test
Tests DPYD variants that reduce dihydropyrimidine dehydrogenase activity. Carriers are at risk of severe toxicity from 5-FU and capecitabine and may need a lower dose.
- Clinical area
- Immunogenetics & thrombophilia
- Method
- Variant panel
- Sample
- EDTA whole blood · Extracted DNA
- Report languages
- EN · AR · RU
When to order
Before starting chemotherapy with 5-FU, capecitabine or tegafur.
Results are reported to the ordering physician and should be interpreted in clinical context.
Request this test
Offer this test to your patients.
Contract pricing and turnaround times are provided on request for laboratories and clinics.
Immunogenetics & thrombophilia